Sensei Biotherapeutics shareholders approve reverse stock split at 1:10-1:30 ratio

Sensei Biotherapeutics, Inc.

Elected directors William Ringo (8.9M for) and John Celebi (9.2M for) to three-year terms.
Ratified Deloitte & Touche as independent auditor for FY2025: 15.8M for, 369.9K against.
Approved reverse stock split authorization (ratio 1:10 to 1:30) at board discretion; 14.7M for, 1.6M against.

item 5.07

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-125484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.